NCI DCT CLINICAL ONCOLOGY PROGRAM WILL BE HEADED BY GREGORY CURT
NCI DCT CLINICAL ONCOLOGY PROGRAM WILL BE HEADED BY GREGORY CURT, who will be returning to the National Cancer Institute after a year at Brown University. Curt had left his position as deputy director of the Division of Cancer Treatment (DCT) last July to head Brown University's residency program. He will return to NCI in July to assume NCI Director Samuel Broder's previous position as chief of DCT's Clinical Oncology Program. While Curt is returning, NCI is losing several senior scientists from its AIDS lab and other officials. NCI's Tumor Cell Biology Laboratory is losing Mika Popovic and Suzanne Gartner, who are joining the Primate Research Institute at New Mexico State University, and Flossie Wong-Staal, who is moving to the University of Southern California. Popovic has been with the Tumor Cell Biology Lab, which is headed by Robert Gallo, since January 1980. He was one of the original authors of the first paper describing HIV. Gartner, a senior staff fellow, joined the lab in 1984. Gartner officially left NCI April 7 and Popovic will leave by the end of the summer. Gallo's lab includes about 40 scientists, of which eight to 10 are senior researchers. In addition to scientists in Gallo's lab, two other NCI officials are leaving or negotiating positions elsewhere. Joseph Cullen, Division of Cancer Prevention and Control deputy director since 1982 will become director of the American Medical Center in Denver by July 1. Daniel Nixon, associate director of the Cancer Prevention Research Program, has been offered a job at the American Cancer Society as vice president for professional education. His new position has not yet been finalized.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth